After a progression-free survival win last year raised hopes for the combo's potential in hepatocellular carcinoma, an overall survival miss brings the study to a close.
MSD, known as Merck & Co in the US and Canada, licensed rights to Lenvima in 2018 in a near-$6 billion deal aimed at developing it as a partner drug to Keytruda. The combination has been approved for ...
11don MSN
A liver transplant might save him — if he can get the drug he needs to stay alive long enough
A health insurance dispute is preventing a North Carolina man from getting a cancer drug his doctors say is necessary.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback